Dallas-based biotechnology startup Colossal Biosciences has secured US$200 million in its latest funding round, increasing its valuation to US$10.2 billion.

Led by TWG Global, this funding brings the company’s total investments to US$435 million since it was founded.

The company’s primary focus is on de-extinction, which includes efforts to revive species such as the woolly mammoth, the dodo, and the Tasmanian tiger.

Co-founder and CEO Ben Lamm has said that the company plans to produce a woolly mammoth calf using a surrogate elephant by late 2028.

This will involve using Asian elephant cells and mammoth genes from ancient samples.